A Modified Risk Set Approach to Biomarker Evaluation Studies

There is tremendous scientific and medical interest in the use of biomarkers to better facilitate medical decision making. In this article, we present a simple framework for assessing the predictive ability of a biomarker. The methodology requires use of techniques from a subfield of survival analysis termed semi-competing risks; results are presented to make the article self-contained. As we show in the article, one natural interpretation of semi-competing risks model is in terms of modifying the classical risk set approach to survival analysis that is more germane to medical decision making. A crucial parameter for evaluating biomarkers is the predictive hazard ratio, which is different from the usual hazard ratio from Cox regression models for right-censored data. This quantity will be defined; its estimation, inference, and adjustment for covariates will be discussed. Aspects of causal inference related to these procedures will also be described. The methodology is illustrated with an evaluation of serum albumin in terms of predicting death in patients with primary biliary cirrhosis.

[1]  D. Harrington,et al.  Counting Processes and Survival Analysis , 1991 .

[2]  D. Oakes,et al.  Semiparametric inference in a model for association in bivanate survival data , 1986 .

[3]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[4]  R. Day,et al.  Adaptation of bivariate frailty models for prediction, with application to biological markers as prognostic indicators , 1997 .

[5]  Sudhir Srivastava,et al.  Markers for early detection of cancer: Statistical guidelines for nested case-control studies , 2002, BMC medical research methodology.

[6]  Debashis Ghosh,et al.  Meta‐analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling , 2012, Biometrics.

[7]  M H Gail,et al.  Evaluating serial cancer marker studies in patients at risk of recurrent disease. , 1981, Biometrics.

[8]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[9]  Robert Tibshirani,et al.  Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy , 1986 .

[10]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[11]  Mitchell H Gail,et al.  On criteria for evaluating models of absolute risk. , 2005, Biostatistics.

[12]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[13]  D. Clayton.  A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence , 1978 .

[14]  D. Oakes.  A Model for Association in Bivariate Survival Data , 1982 .

[15]  P. Grambsch,et al.  Primary biliary cirrhosis: Prediction of short‐term survival based on repeated patient visits , 1994, Hepatology.

[16]  P. Heagerty,et al.  Time‐Dependent Predictive Accuracy in the Presence of Competing Risks , 2010, Biometrics.

[17]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[18]  Debashis Ghosh,et al.  On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm , 2009, Biometrics.

[19]  Z. Ying,et al.  A simple resampling method by perturbing the minimand , 2001 .

[20]  Tianxi Cai,et al.  Evaluating Prognostic Accuracy of Biomarkers under Competing Risk , 2012, Biometrics.

[21]  M. Pepe,et al.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. , 2004, American journal of epidemiology.

[22]  Jason P. Fine,et al.  On semi-competing risks data , 2001 .

[23]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.